Added to YB: 2024-02-01
Pitch date: 2024-01-31
LLY [bullish]
Eli Lilly and Company
+60.96%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally.
Market Cap
$893.2B
Pitch Price
$638.37
Price Target
N/A
Dividend
0.60%
EV/EBITDA
31.99
P/E
48.80
EV/Sales
15.58
Sector
Pharmaceuticals
Category
growth
Show full summary:
Eli Lilly: GLP-1's Potential In More Indications Should Unlock Significant Value
$LLY to gain from GLP-1 drugs, est. $150B US sales by 2030. ZepBound beats $NVO's Wegovy in obesity Rx. Retatrutide shows promise in Ph2. Strong pipeline w/ immuno-onc & gene Rx. Predict $50+ EPS for 2030 driven by GLP-1 rev. Q4 earnings & 2024 guide 2/6.
Read full article (3 min)